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IL-6 is apleiotropic cytokine produced by avariety ofcell types, including fibro-
blasts, endothelial cells, monocytes, andT cells. Whilethismoleculehasbeen identified
independently in several different bioassays as B cell stimulatory factor 2, IFN-R2,
26-kd protein, plasmacytoma growth factor, and hepatocyte stimulating factor, the
amino acid sequence ofproteins, the molecularcloning ofthecorrespondinggenes,
and the availability ofrecombinant proteins have led to the conclusion that all the
biological activities can be attributed to one and the same polypeptide, now called
IL-6 (reviewed in references 1-3). This glycoprotein induces the final maturation
ofB cells into Ig-secreting cells (4), the proliferation of plasmacytomas, B cell hy-
bridomas, and EBVtransformed B lymphoblastoid cells (5-9), the IL-2 production,
proliferation, and differentiation ofT cells(10-13), theproliferation and differentia-
tion ofhematopoietic precursors (14), and the production of acute phase proteins
by hepatocytes (15).
It is wellknown that plasmacytomascanbeinduced in ahigh percentage ofBALB/c
mice after the intraperitoneal injection ofmineral oil or pristane, which evokes the
formation ofa chronic granulomatous tissue thatconsists primarilyofmacrophages
and neutrophils (16). A macrophage-derived factor has been demonstrated to be
essential for in vitro survival andproliferation ofmurine plasmacytomas, suggesting
the involvementofthe factor in theestablishmentandmaintenance in vivo ofpristane-
inducedmurine plasmacytomas (17-19). Thedetermination ofamino acid sequence
oftheplasmacytoma growth factor and the cloning ofacorresponding gene revealed
that the factor was a murine equivalent ofhuman IL-6 (5, 8, 20). In humans, the
involvement ofIL-6 has been also suggested in the malignant transformation of B
cells. Myelomacells freshly isolated from patients with multiple myelomaproduced
andresponded to IL-6, and anti-IL-6 antibody inhibitedtheirin vitroproliferation.
These observations led to the proposition that an IL-6 autocrine mechanism might
operate in oncogenesis of human myelomas (21).
The generation ofcells that constitutively express IL-6-R and secrete IL-6 should
provide a model system to assess the role of IL-6 as an autocrine growth factor in
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B cell malignancy. In the following study, we present the results obtained after in-
troduction of an expression vector carrying an IL-6 cDNA into an IL-6-dependent
murine B cell line. The transfectants proliferated in vitro autonomously through
an IL-6 autocrine mechanism and were found to be highly tumorigenic in vivo. Our
results indicate that the autocrine action of IL-6 is of importance in the process of




A 650-by-long Bgl II-Ban I fragment of the plasmid PSP64T 26K
carrying a human IL-6 cDNA (22) was rendered blunt-ended, ligated to Xho I linkers, and
cloned into the Xho I site ofthe expression vector BCMGNeo (23) in the proper orientation.
In the resulting plasmid, BCMGNeo IL-6, the transcription ofIL-6 cDNA, from which most
of the 3' untranslated region containing A and T nucleotide-rich sequences responsible for
the destabilization of transcripts has been deleted, is under the control of the promoter/en-
hancer of human CMV.
Preparation ofHumanrIL-6.
￿
Cell lines secreting a large quantity of human rIL-6 were es-
tablished by transfection of Ig-nonproducing murine myeloma X63-Ag8.653 cells (24) with
the IL-6 cDNA expression vector BCMGNeo IL-6, as described previously (25). The media
conditioned by G418-resistant stable transfectants contained >105 U/ml of IL-6 activity and
were used as the source of rIL-6.
Preparation ofPolyclonal Anti-human IL-6Antibodies.
￿
Human rIL-6, prepared from culture
supernatants of the IL-6 cDNA-transfected X63-Ag8.653 cells by SDS-PAGE, was mixed
with CFA and injected subcutaneously into rabbits at 2-wk intervals for 2 mo to obtain an
antiserum against human IL-6. Serum from preimmunized rabbits was used as control.
Establishment of IL-6-dependent Cell Lines.
￿
BALB/c mice (Japan SLC Inc., Hamamatsu,
Japan) were injected intraperitoneally with 50 p,g ofEscherichia coli 055:B5 LPS (Difco Labora-
tories, Detroit, MI) 3 d before fusion of their spleen cellswith X63-Ag8.653 myeloma cells.
Among hybridomas growing in media containing HAT (100 AM hypoxanthine, 0.4 AM
aminopterin, 16 AM thymidine) and 500 U/ml ofrIL-6, those ofwhich survival and prolifer-
ation were absolutely dependent on exogenously supplied IL-6 were selected and cloned by
the limiting dilution method. These IL-6-dependent cell lines were maintained in RPMI
1640 medium supplemented with 10% FCS (Gibco Laboratories, Grand Island, NY), 100
U/ml ofpenicillin-streptomycin (Gibco Laboratories), 2 MM L-glutamine (Gibco Laborato-
ries), 5 x 10-5 M 2-ME, and 500 U/ml of rIL-6.
DNA Transfection.
￿
DNA transfection was performed by the protoplast fusion technique
(26). Bacteria bearing the plasmid BCMGNeo IL-6 were converted to protoplasts and fused
to an IL-6-dependent cell line (F12-28) by using polyethylene glycol 2,000 (Wako Pure Chemical
Industries, Osaka, Japan). 2 d afterthe fusion, cells were cultured in the presence of0.8 mg/ml
of G418 (Gibco Laboratories) and 500 U/ml of rIL-6. Among G418-resistant transfectants,
those grown even in the absence of exogenous IL-6 were selected and then subcloned by the
limiting dilution method. Subclones of transfectants were thereafter maintained in media
without G418 and exogenous IL-6.
Assayfor IL-6 Activity.
￿
IL-6 activity was measured by the [3H]thymidine incorporation
of an IL-6-dependent cell line (B45-3) established by fusion of rat spleen cells with murine
B cell hybridoma SP2/0 cells (N. Tohyama et al., unpublished observations). Serial dilutions
of IL-6 were incubated with 5 x 103 B45-3 cells in a volume of 0.2 ml for 48 h, followed
by a 6-h pulse of 1 ACi ['H]thymidine (Amersham Japan, Tokyo, Japan). 1 U of activity




Cells were cultured at 2 x 103 cells/0.2 ml (Figs. 1 and 3) or at
indicated densities shown in Fig. 4, in the presence or absence of rIL-6 for 72 h (Figs. 1
and 3) or for 48 h (Fig. 4), followed by a 6-h pulse of 1 tcCi of [3H]thymidine, and [3H]thymi-
dine incorporation was measured by liquid scintillation counting. In the growth inhibition
assay, rabbit anti-IL-6 antiserum or preimmune serum was added at the start ofthe culture.Cell growth was also measured by counting cell numbers. Cells were seeded at 5 x 103 in
a 0.2-ml culture in the presence or absence ofrIL-6 (500 U/ml). Number of viable cells was
determined every 12 h up to 72 h by the trypan blue dye exclusion method.
Tumorigenicity Assay. F12-28 cells untransfected and transfected with BCMGNeo or
BCMGNeo IL-6 were washed with and resuspended in PBS at a concentration of 106
cells/ml. Groups of four or five BALB/c mice (6-7 wk old; Japan SLC Inc., Hamamatsu,
Japan) and BALB/c nude mice (6-7 wk old; CLEA Japan Inc., Tokyo, Japan) were injected
subcutaneously into the axillae with 105 cells. Mice were monitored every 5 d for the ap-
pearance of solid tumors.
Results
Establishment of an IL-6-dependent Cell Line (F12-28).
￿
Spleen cells from BALB/c
mice injected with LPS were fused with Ig-nonproducing myeloma X63-Ag8.653
cells derived from BALB/c mice, and HAT selection was performed in the presence
of exogenously supplied rIL-6. While the majority of B cell hybridomas established
under this condition were able to grow even in the absence of exogenous IL-6 (Fig.
1 B), very few clones turned out to be absolutely dependent on exogenous IL-6 for
their survival and proliferation. F12-28, one of the subclones derived from these IL-
6-dependent clones, was further characterized and used for the following studies.
F12-28 cells responded by proliferation to rIL-6 in a dose-dependent manner (Fig.
1 A) and died within 72 h, unless rIL-6 was supplied (Fig. 2 A).
Autonomous Growth ofIL-6 cDNA-transfected F12-28 Cells.
￿
An IL-6 cDNA expres-
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IL-6-dependent proliferation of F12-
28 cells. (A)An IL-6-dependent B cell line, F12-
28; (B) an IL-6-independent B cell hybridoma
line, C2. Cells (2 x 103) were cultured in a
volume of0.2 ml for 72 hin the absence(")or
presence (")of serially diluted rIL-6, followed
by a 6-h pulse of [3Hlthymidine.
FIGURE 2. IL-6 cDNA-transfected F12-28
cells grow withoutrequirement ofexogenous
IL-6. (A)Untransfected F12-28 cells;(B)F12-
28 cellstransfected with thevector alone; (C)
IL-6 cDNA transfectant IL-6A14. Cellswere
seeded at 5 x 103 in a 0.2-ml culture in the
absence (O) or presence (") of 500 U/ml
rIL-6. Number ofviable cells wasdetermined
every 12 h up to 72 h by the trypan blue dye
exclusion method.392
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sionvector (BCMGNeo IL-6) was constructedby insertingacDNAencoding human
IL-6 (22, 27) into the bovine papilloma virus-based vector BCMGNeo (23). To en-
hancetheexpression, most ofthe 3' untranfated region containing A and Tnucleo-
tide-rich sequencesresponsible for thedestabilizationoftranscripts (28, 29) hasbeen
deleted from thecDNA. InBCMGNeo IL-6, the promoter/enhancerofhumanCMV,
and the splicing/poly(A) addition signals of the rabbit 0 globin gene were placed
for the transcription of IL-6 cDNA; in addition, the neomycin resistance gene was
inserted forthe selection ofstable transfectants. Thoughhuman IL-6 cDNA is 35%
differentfrommurine IL-6 cDNAatthenucleotide sequenceand58% atthededuced
amino acids (20), human IL-6 is active on mouse cells (7).
To generate cell lines ofB lineage that constitutively express IL-6-R and secrete
IL-6, an IL-6-dependent cell line (F12-28) was transfected with BCMGNeo IL-6
bymeans ofthe protoplastfusion technique (26). AmongG418-resistant stable trans-
fectants, N80% ofclones were able to grow in the absence ofexogenously supplied
IL-6 (Fig. 2 C), while any of F12-28 cells transfected with the vector BCMGNeo
alonewere not(Fig. 2 B). The IL-6 cDNAtransfectants grownwithout any require-
ment forexogenous IL-6 were subcloned, and five independent clones, IL-6A2, IL-
6A6, IL-6A14, IL-6132, and IL-6B8, were established for further analysis (Table I).
SecretionofIL-6 byIL-6 cDNA Transfectants.
￿
To elucidate whetherthe autonomous
growth ofIL-6cDNA-transfected F12-28 cellsismediated byan IL-6 autocrinemech-
anism, we first examined the presence of IL-6 activity in the culture supernatant
ofthetransfectants. The IL-6cDNA-transfected F12-28 cellssynthesizedandsecreted
IL-6 ranging from 70 to 880,000 U/106 cells/ml in a 48-h culture, whereas no de-
tectable IL-6 was foundin mediaconditioned byF12-28 cells untransfected ortrans-
fected with the vector alone, or the fusion partner X63-Ag8.653 or in the media
ofan IL-6-independent B cell hybridoma(C2) (Table I). Northern blot analysis re-
vealed that the IL-6 cDNA transfectants expressed human IL-6-specific transcripts
carrying the sequence derived from the expression vector, indicating that the IL-6
production of the transfectants was caused by the introduced human IL-6 cDNA
and not by the activation of an endogenous IL-6 gene (data not shown).
TABLE I
Secretion of IL-6 by IL-6 cDNA-transfected F12-28 Cells
Media conditioned for 48 h by cells (106/ml) were tested for IL-6 activity on
an IL-6-dependent cell line B45-3 by [sH]thymidine incorporation (see Materials
and Methods). 1 U of activity was defined as the amount of IL-6 that induced
50% of maximal proliferation of B45-3 cells.
Cell line Plasmid IL-6 secretion
X63-Ag8.653 - <0.1 U/ml




IL-6A2 BCMGNeo IL-6 880,000
IL-6132 BCMGNeo IL-6 34,000
IL-6A6 BCMGNeo IL-6 4,900
IL-6A14 BCMGNeo IL-6 1,800
IL-6B8 BCMGNeo IL-6 70Anti-IL-6Antibodies Inhibit the Proliferation ofIL-6cDNA Transfectants.
￿
We next ex-
amined whether secreted IL-6 played a role as an autocrine growth factor for the
proliferation of IL-6 cDNA transfectants. For this purpose, polyclonal antibodies
to IL-6 were prepared by injecting rabbits with purified human rIL-6. The serum
from immunized rabbits completely inhibited the proliferation of IL-6-dependent
F12-28 cells stimulated with rIL-6 (Fig. 3 A). The inhibition of proliferation was
totally abolished by the addition ofexcess rIL-6. In contrast, no growth inhibition
was caused by the serum from preimmunized rabbits. Moreover, the serum from
immunized rabbitshad no effect on the proliferationofthe IL-6-independent B cell
hybridoma C2 (Fig. 3 B). These results confirmed that the inhibitory effect ofthe
antiserum was due to the specific activity against IL-6. The proliferation of IL-6
cDNA transfectants was suppressed by the addition ofthe anti-IL-6 antiserum; the
growth inhibition was almost complete in case oflower producers of IL-6 such as
IL-6A14(Fig. 3 C) andIL-6B8, partial inIL-6A6, and littleornone in higher producers
such as IL-6A2 and IL-6B2 (data not shown). This observation indicated that IL-6




IL-6A14 cells maintained at relatively high density (2-5 x 105 cells/ml) were
replated at various cell densities ranging from 103 to 1.6 x 104 cells/ml in the pres-
ence or absence of exogenous IL-6, and their proliferation was determined by
[3H]thymidine incorporation. The proliferation rate, expressed as [3H]thymidine
incorporation per cell, declined as the cell density became lower in the absence of
exogenous IL-6 (Fig. 4 B). However, the addition of rIL-6 rendered the rate con-
stant regardless ofcelldensity, asobservedinuntransfectedormock-transfected F12-28













Anti-IL-6antibodies inhibitthe proliferationof IL-6 cDNA-transfected F12-28 cells.
(A)Untransfected F12-28 cells (2 x 103/0.2 ml)were cultured in thepresence of 30 U/ml rIL-6
for 72 h, followed by a6-hpulseof[3H]thymidine. At the beginningof theculture, serially diluted
rabbit anti-IL-6antiserum("), preimmuneserum(O), or control medium (0)wasadded into
culture. An excess amount ofrIL-6(3,000 U/ml)was addedtogether with the highestconcentra-
tion (1:100 dilution)of anti-IL-6 antiserum (A). IL-6-dependent Bcell hybridomaC2 (B)and
IL-6 cDNA transfectant IL-6A14 (C)were cultured without rIL-6 in the presence of anti-IL-6
antiserum ("), preimmune serum (O), or control medium (0).394
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Therate of cell proliferation as a func-
tion ofcell density in IL-6 cDNA-transfected F12-28
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at different cell densities were cultured for 48 h in
the absence (O)or presence of 500U/ml rIL-6(0),
°
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followed by a 6-h pulse of [3H]thymidine. The
proliferation rate expressed as [3H]thymidine incor-
poration (cpm)percell at differentdensities is plotted
-
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growth of the transfectants required accumulation of autogenous IL-6 in the sur-
rounding media. Indeed, the dependency of proliferation on cell density was more
prominent in lower producers of IL-6 than in higher producers. The growth of the
lowest IL-6 producer IL-6B8 cells was greatly slowed, and they finally died when
they were maintained at too low a density (data not shown).
Enhanced Tumorigenicity ofIL-6 cDNA Transfectants.
￿
All the growth properties of
the IL-6 cDNA transfectants shown above indicatedthat the production of IL-6 en-
abled IL-6-dependent cells to acquire growth autonomy in vitro through an auto-
crine self stimulation. To assess the tumorigenicity of these cells in vivo, BALB/c
nude mice were injected subcutaneously with 105 cells of each clone and monitored
for tumor appearance and growth. As shown in Table II, the IL-6 cDNA transfec-
tants expressing high levels of IL-6, such as IL-6A2, IL-6112, and IL6-A6, formed
growing tumors as early as 5 d after inoculation. All animals injected with these
transfectants fell severely sick and died by 21 d. In contrast, mice inoculated with
F12-28 cells untransfected or transfected with the vector without the cDNA insert
(Vec 3 and Vec 61 in Table II) developed tumors >20 d after injection and survived
foras long as 50 d. Among the IL-6 cDNA transfectants, the latency period of tumor
developmentapparently correlated with the levelof IL-6 secreted by individual clones:
ahigher producer of IL-6 gave rise to a tumor in a shorter period. Tumorigenicity
of the transfectants in syngeneic BALB/c mice was comparable with that in nude
mice, that is, the IL-6 cDNA transfectants formed tumors and killed animals in a
much shorter period than the mock transfectants, and the inverse correlation was
observed between the latency period and the level of IL-6 production (Table II).
Discussion
The concept of autocrine stimulation of cell proliferationpostulates that cellscould
escape from normal growth controlandbecome malignant by the endogenous produc-
tion of growth factors that act on themselves via functional external receptors (30,
31). The autocrine action o£ growth factors such as transforming growth factor and
platelet-derived growth factor has been demonstrated in certain virus-transformed
cells (32-35). Thereis ample evidence showing that autocrine self stimulation could
be involved in malignant transformation of lymphoid cells (21, 36-40). We have re-
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IL-2-dependent Th cells that the aberrant activation of the IL-2 autocrine circuit
could lead T cells to malignant transformation, thus providing a model system for
the understanding of the pathogenesis of adult T cell leukemia caused by infection
of CD4+ Th cells with human T cell leukemia virus type 1 (23).
In thepresent study, we experimentally created cell linesthat proliferated in vitro
autonomously throughan IL-6 autocrinemechanismby introducingtheIL-6 cDNA
expression vector into an IL-6-dependent B cell line. The autocrine nature of the
proliferation is warranted by the following evidence : whereas F12-28 cells untrans-
fected or transfected with thevector alone required exogenous IL-6 for survival and
proliferation, the IL-6 cDNA transfectants did not. The transfectants secreted bio-
logicallyactive IL-6 into the culture media. Further, their proliferationwas inhibited
by antibodies to IL-6. The growth ofthe transfectants was afunction ofthe cell density.
The establishment ofcell linesthat proliferated autonomously through IL-6 auto-
crineself stimulationmade it possible to examine therelationship between IL-6 au-
tocrine mechanism and tumorigenicity. The IL-6 cDNA transfectants were found
to be highly tumorigenic when inoculated into syngeneic as well as athymic mice
(Table II). The latency period of tumordevelopment correlated apparently with the
levelof IL-6 secreted by individual clones; that is, the transfectants secretingahigher
titerof IL-6 developed tumors in shorterperiods. This fact indicatedthat autogenous
IL-6 contributed to the tumorigenicity of the transfectants. Cells obtained from tumors
proliferated in vitro in an IL-6 autocrine fashion indistinguishable from that of the
inoculated cells (datanot shown), discountingthe possibility that IL-6 cDNA trans-
fectants could become maliganant in vivo by a mutation(s) that abrogated the re-
quirement for IL-6 autocrine self stimulation.
While F12-28 cells transfected with the expression vector alone were absolutely
dependent on exogenousIL-6 forsurvival and proliferation in vitro (Fig. 2 B), they
produced tumors in vivo even afteramuch longer latencyperiod than the IL-6 cDNA
transfectants did (Table II). This cannot be due to the introduced expression vector
or the consequence of DNA transfection, because untransfected F12-28 cells gave
rise to tumors with a latency period comparable with that of mock transfectants.
The in vivo growth of the IL-6-dependent cells might be explainedby the paracrine
action of a growth factor(s) such as IL-6 produced by cellsin thehost animals. Whereas
tumors developed in mice injected with the IL-6 cDNA transfectants were almost
exclusively made up of transfectants themselves, those in mice injected with F12-28
cells contained not only the inoculated cells but also numerous host cells, including
fibroblasts, lymphocytes, and macrophages, which arepotent producers ofIL-6 (un-
published observation) . Furthermore, cells, of tumors produced by F12-28 cells re-
tained the IL-6 dependence for their in vitro growth. These observations suggest
aparacrine growth of factor-dependent cells in vivo. Alternatively, F12-28 cells might
have already undergone some genetic alterations toward the acquisition of malig-
nancy like other immortalized cell lines, and could grow in vivo without any re-
quirement ofIL-6, even though they arestrictly dependenton IL-6 in vitro. Whatever
themechanism of in vivo growth of IL-6-dependent cells is, our results indicate that
the acquisition of the ability to produce IL-6 greatly potentiates the tumorigenicity.
Tumors produced by the transfectants secreting large amounts of IL-6 were so
malignantthat host animals fell severely sick and died by 21 d afterinoculation with
105 cells. The high degree of malignancy did not seem to be attributed only to thegrowing tumors in themselves, because the recipient mice died even before tumors
became large, in contrast to mice injected with mock transfectants. Blood taken from
the mice bearing tumors of the IL-6 cDNA transfectants was very viscous andcon-
tained an elevated level of acute phase proteins, such as a2-macroglobulin along
with the reciprocal reduction of albumin detected by immunoelectrophoresis (un-
published observation). In the sera of the mice, 103 to 4 x 105 U/ml of IL-6 activity
was detected, while <10 U/ml was detected in those of mice injected with the mock
transfectants. These observations suggested that IL-6 produced by tumors had un-
desirable effects on host animals. In humans, such systemic effects ofIL-6 have been
observed in patients with cardiac myxomas producing IL-6 (41).
Kawano et al. (21) have reported that myelomacells freshly isolated from patients
secreted biologically active IL-6 and expressed its receptors. In about half of the
cases, myeloma cells showed responsiveness to IL-6, and their proliferation in vitro
was inhibited by anti-IL-6 antibodies. These growth properties ofhuman myeloma
cells are similar to those of our transfectants, although the levels of IL-6 produced
by human myeloma cells were low as compared with those produced by the IL-6
cDNA transfectants. On the other hand, Klein et al. (42) have shown that the IL-6
production found in the bone marrows of patients with multiple myeloma was as-
signed to adherent cells ofthe bone marrow environment but not to myeloma cells,
suggesting a paracrine rather than autocrine growth of myeloma cells, as observed
in pristane-induced murine plasmacytomas (17-19). Since our results provide evi-
dence that the establishment of IL-6 autocrine loop enhances the tumorigenicity
ofIL-6-dependent cells, it is possible to assume that myelomacellsproliferate through
a paracrine mechanism in an early stage of oncogenesis and step up into a more
advanced stage by acquiring the ability to produce IL-6. They might become inde-
pendent of IL-6 autocrine self stimulation in a final stage, as myeloma cells from
patients with stage III of multiple myeloma showed a poorer or no response to IL-6
(43). Taken together, we conclude that the dysregulated expression of IL-6 and its
receptors confers on B cells a strong selective growth advantage in an autocrine fashion
and results in the induction and/or progression of the malignant state of B cells.
Summary
We introduced an IL-6 cDNA expression vector into a murine B cell line, the
growth ofwhichdefinitely required the presence of exogenous IL-6. The transfected
cells secreted substantial amounts of IL-6, to which they themselves responded by
proliferating without further requirementofexogenousIL-6. The proliferationwas
adirect function of cell densityandwasinhibitable by antibodies to IL-6, indicating
the autocrinenature ofthe growth. The IL-6 cDNA-transfected cells displayed greatly
enhanced tumorigenicity when inoculated into syngeneic and nude mice. Our data
suggest that an IL-6 autocrine self stimulation confers on B cells a selective growth
advantage and results in the induction or progression ofthe malignant stateofB cells.
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